BAX Stock Analysis — Baxter International
Sector: Healthcare
AI Verdict
Baxter trades at 9.5x next year's earnings, which is cheap for the sector, but with -12.5% revenue growth and a business under pressure, you're betting on a turnaround rather than paying for proven stability.
Competitive Moat
Baxter International manufactures essential hospital products like IV solutions, dialysis equipment, and infusion systems, with long-term contracts and regulatory hurdles creating sticky customer relationships. Its scale in hospital supply chains and deep integration with clinical workflows make it difficult for new entrants to displace.
Summary
Baxter's stock is under pressure after a -39.91% one-year return and shrinking sales, but it trades at just 9.5x forward earnings.
Where It Stands
Despite a 72.1 RSI signaling overbought territory, Baxter's 1-year return is -39.91% and its 9.5x forward P/E is far below the healthcare sector median of 22x.
Key Metrics
- RSI: 72.1 — Overbought
- Forward P/E: 9.5x
- Revenue Growth: -0.1%
- Market Cap: $9.4B
- Dividend Yield: 0.00%
- 1-Year Return: -39.91%
- 52-Week High: $32.68
- 52-Week Low: $15.73
Analyst Consensus
5 Buy · 16 Hold · 1 Sell (22 analysts)
Bull Case
At 9.5x forward earnings, the stock is priced for pessimism, leaving room for upside if the company stabilizes after a -12.5% revenue drop.
Bear Case
With an RSI of 72.1 and no growth in sight, a pullback could easily erase recent gains, especially if the P/E reverts even lower on further disappointment.
Catalyst to Watch
Watch for any signs of revenue stabilization or turnaround in quarterly results, as even modest improvement could rerate the stock given its low valuation.